Towards Healthcare
U.S. Osteoarthritis Therapeutics Market to Grow at 7.14% CAGR till 2034

U.S. Osteoarthritis Therapeutics Market Driven by New Therapies

Based on market forecasts, the U.S. osteoarthritis therapeutics market, projected at USD 3.27 billion in 2024, is expected to reach USD 6.46 billion by 2034, growing at a CAGR of 7.14% over the forecast period. The severe disease burden, the limited efficacy of current therapies, and the demand for innovative solutions raise the importance of osteoarthritis therapeutics. The U.S. dominated the market in 2024, led by the unmet clinical needs and advancements in research and development.

Content

  • Insight Code: 6230
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The U.S. osteoarthritis therapeutics market is worth USD 3.5 billion in 2025, and by 2034, it is forecasted to hit USD 6.46 billion, registering a CAGR of 7.14% over the decade.

The U.S. osteoarthritis therapeutics market includes four segments such as therapy/drug class, route/mode of administration, indication/joint site, disease severity/treatment line, and by region.

Some key players include Novartis AG, Johnson & Johnson, Sanofi S.A., Pfizer Inc., Eli Lily and Company, etc.

Key trends include advanced biologics, precision therapies, regenerative medicine, adjunctive and evolving therapies, and patient-specific treatments.

ARPA-H, FDA, NIH, OAI, NITRO.
Any Questions